Generic Vaniqa Availability
VANIQA (eflornithine hydrochloride - cream;topical)
Approval date: July 27, 2000
Strength(s): 13.9% [RLD]
Has a generic version of Vaniqa been approved?
No. There is currently no therapeutically equivalent version of Vaniqa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vaniqa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Topical composition for inhibiting hair growth
Issued: July 15, 1997
Inventor(s): Boxall; Brian Alfred & Amery; Geoffrey Wilfred & Ahluwalia; Gurpreet S.
The present invention embraces a topical composition for inhibiting mammalian hair growth, particularly human beard hair growth (including hirsutism), comprising a water-soluble, hair-growth-inhibiting agent dispersed in an oil-in-water emulsion in the form of a lotion or cream. The invention also embraces a method of inhibiting mammalian hair growth by applying an effective amount of the above composition to the skin. The invention further embraces a topical composition for delivering a pharmacological agent to the skin.Patent expiration dates:
- July 15, 2014✓
- July 15, 2014
- Vaniqa Consumer Information (Drugs.com)
- Vaniqa cream Consumer Information (Wolters Kluwer)
- Vaniqa Consumer Information (Cerner Multum)
- Vaniqa Topical Advanced Consumer Information (Micromedex®)
- Vaniqa AHFS DI Monographs (ASHP)
- Eflornithine cream Consumer Information (Wolters Kluwer)
- Eflornithine topical Consumer Information (Cerner Multum)
- Eflornithine Injection Advanced Consumer Information (Micromedex®)
- Eflornithine Topical Advanced Consumer Information (Micromedex®)
- Eflornithine AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|